Epoetin5000 IU

Epoetin 5000 IU alfa is a recombinant human Epoetin 5000 IU used to stimulate red blood cell production in patients with anaemia due to several different causes. Approved uses include:

• Anaemia associated with chronic kidney disease (CKD), in patients on dialysis and those not on dialysis
• Anaemia due to myelosuppressive chemotherapy in patients with certain non-myeloid cancers, to reduce the need for blood transfusion
• Anaemia related to zidovudine treatment in HIV-infected patients
• Reduction of allogeneic blood transfusion needs in certain patients undergoing elective, non-cardiac, non-vascular surgery, as an adjunct to other measures

Epoetin 5000 IU alfa is not a substitute for emergency transfusion and does not treat the underlying disease causing anaemia.

Contains recombinant human Epoetin 5000 IU alfa as the active ingredient, supplied as an injectable solution in various strengths (commonly ranging from 2,000 to 40,000 international units per mL, depending on the presentation). Exact strengths and presentations vary by product; refer to the specific product's label.

Epoetin 5000 IU alfa is an injectable, laboratory-made version of Epoetin 5000 IU, a hormone the kidneys normally produce to stimulate red blood cell formation in the bone marrow. It is used to treat anaemia in patients with chronic kidney disease, in cancer patients receiving certain chemotherapy regimens, and in a few other specific clinical situations, helping to raise red blood cell counts and reduce the need for blood transfusions.

Therapeutic Class: Erythropoiesis-Stimulating Agent (Anti-anaemic)

Epoetin 5000 IU alfa stimulates erythropoiesis (red blood cell production) by interacting with Epoetin 5000 IU receptors on red cell progenitor cells in the bone marrow. It is typically given intravenously or subcutaneously, with subcutaneous absorption being slower, resulting in a longer-lasting effect at a given dose. The onset of a measurable increase in red blood cell production typically takes 1-2 weeks, and a rise in haemoglobin is usually seen within 2-6 weeks.

• Administered by intravenous or subcutaneous injection; the subcutaneous route is commonly used in patients not on haemodialysis
• Do not shake the vial, as vigorous shaking may denature the drug
• Each vial is for single use only (for preservative-free formulations); discard unused portion
• Multi-dose vials containing benzyl alcohol should not be used in neonates, infants, pregnant, or breastfeeding women

No major pharmacokinetic drug interaction studies have been performed, but the following should be assessed by a healthcare professional:

• Concurrent use with other drugs that increase blood pressure or clotting risk should be monitored, given Epoetin 5000 IU's own effect on blood pressure and clotting tendency
• Iron supplementation is often needed alongside Epoetin 5000 IU therapy to support increased red blood cell production and should be coordinated with the treating physician

Common side effects

• Hypertension (raised blood pressure)
• Joint pain (arthralgia)
• Injection site pain
• Headache
• Nausea, vomiting
• Cough, fever

Serious side effects (seek urgent medical attention)

• Signs of a blood clot: leg swelling or pain, chest pain, sudden shortness of breath
• Signs of stroke or heart attack: sudden weakness, slurred speech, chest pain
• Signs of a severe allergic reaction: swelling of the face or throat, difficulty breathing
• Signs of pure red cell aplasia: severe, worsening anaemia despite treatment
• Seizures

Pregnancy

Data on Epoetin 5000 IU alfa use in human pregnancy are limited; animal studies have shown some evidence of harm at high doses. Use during pregnancy should occur only if the treating physician determines it is necessary, weighing the risk of untreated maternal anaemia.

Breastfeeding

It is not known whether Epoetin 5000 IU alfa passes into human milk in clinically significant amounts. Multi-dose (benzyl alcohol-containing) formulations are contraindicated in breastfeeding women; a preservative-free formulation should be used if treatment is needed, under medical guidance.

• Cardiovascular risk: Erythropoiesis-stimulating agents increase the risk of death, myocardial infarction, stroke, and other serious cardiovascular events when administered to target a haemoglobin level greater than 11 g/dL; use the lowest dose that reduces the need for transfusion.
• Increased mortality/tumor progression in cancer: In some studies, erythropoiesis-stimulating agents shortened overall survival or increased risk of tumor progression in patients with certain cancers; use only for chemotherapy-induced anaemia in the approved setting and at the lowest effective dose.
• Hypertension: Blood pressure should be adequately controlled before initiating therapy and monitored regularly during treatment.
• Seizures: Increased risk observed, particularly in the first 90 days of therapy; monitor for new-onset seizures, especially with rapid haemoglobin rise.
• Regular monitoring of haemoglobin and iron status is required throughout treatment.

Overdose can lead to excessive haemoglobin elevation (polycythemia), which increases the risk of hypertension and thromboembolic complications such as stroke or heart attack. Suspected overdose should be evaluated by the treating medical team; management may include withholding doses and, in significant polycythemia, therapeutic phlebotomy, as clinically indicated.

Store in a refrigerator at 2-8°C; do not freeze or shake. Protect from light. Do not use if the solution is discolored or contains particulate matter. Follow the specific product's instructions for any allowances for brief periods at room temperature.

• Pediatric CKD patients (1 month-16 years, on dialysis): Established use for anaemia associated with CKD requiring dialysis; safety and efficacy in CKD patients younger than 1 month are not established.
• Pediatric cancer patients: Safety and efficacy in chemotherapy-associated anaemia have not been established in patients younger than 5 years.
• Elderly: Use with the same cardiovascular monitoring precautions as other adults.

For CKD, treatment is typically ongoing, with the dose adjusted based on haemoglobin response. For chemotherapy-associated anaemia, treatment is continued until completion of the chemotherapy course. Duration for perioperative use follows the specific surgical protocol. The treating physician determines the appropriate duration based on the clinical indication and ongoing monitoring.

Drug Class: Recombinant human Epoetin 5000 IU

Epoetin 5000 IU alfa mimics the action of the body's natural Epoetin 5000 IU hormone, binding to receptors on immature red blood cells in the bone marrow and stimulating their division and maturation into mature red blood cells. This increases the number of circulating red blood cells, raising haemoglobin and reducing the symptoms and transfusion needs associated with anaemia.

Epoetin 5000 IU alfa is indicated for pediatric patients 1 month to 16 years of age for treatment of anaemia associated with chronic kidney disease requiring dialysis. Safety and efficacy have not been established in CKD patients younger than 1 month, or in cancer patients on chemotherapy younger than 5 years. Dosing in eligible pediatric patients should be individualized by a specialist based on haemoglobin response.